Canadian New Drug Submission for SCENESSE in EPP filed
Filed with ASX · · 3 pages · English
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL delivers increases in annual revenue, profit
- Appendix 4E and Annual Report to Shareholders 2024
- Vitiligo and Operational Update
- Afamelanotide Assists DNA Repair Response Following UVR
- CLINUVEL extends Managing Director Employment Agreement
Later from Clinuvel Pharmaceuticals
- Managing Director Presentation
- CLINUVEL prioritises three strategic programs
- SCENESSE dosage expansion under review by EMA
- Chair's letter to Shareholders
- Health Canada validates SCENESSE New Drug Submission
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals